Metformin as a Neoadjuvant to Chemotherapy in Locally Advanced and Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Abstract
Several clinical trials have investigated the potential role of metformin as an adjunct to chemotherapy. This meta-analysis aims to assess its efficacy and safety as an adjunct to chemotherapy based on the results of the available RCTs. A comprehensive search was conducted through 5 databases using relevant terms for breast cancer and metformin. PRISMA guidelines were followed. Screening and data extraction steps were performed independently by 2 authors. Meta-analysis was performed on RevMan. A random-effects model was used in case of significant heterogeneity; otherwise, a fixed-effects model was used. Eight studies were included in the systematic review with 582 patients. The overall pathological response rate was better in the metformin (M-Chemo) group compared to the chemotherapy alone (Chemo) group (RR = 1.30, 95% CI [1.14, 1.50], P = .0002). Although the complete pathological response rate did not differ (RR = 1.291, 95% CI [0.977, 1.706], P = .073), the number of patients with no pathological response was significantly less in the M-Chemo group (RR = 0.44, 95% CI [0.20, 0.95], P = .04). Patients requiring breast conservative surgery after the treatment course were more in the M-Chemo group (RR = 1.52, 95% CI [1.15, 2.01], P = .003), whereas the number of patients planned for mastectomy did not differ (RR = 0.90, 95% CI [0.80, 1.02], P = .09). Adverse events were similar between groups, except for higher rates of grade 3 to 4 diarrhea in the M-Chemo group (RR = 7.09,…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 582 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.